Kenvue Bondholders Swap Into Kimberly-Clark Notes, Leaving Holdouts Without Most Covenants

Kimberly-Clark settled its exchange for seven Kenvue note series, and the stock leaves the NYSE on November 12.

Share
Kenvue Bondholders Swap Into Kimberly-Clark Notes, Leaving Holdouts Without Most Covenants

Kimberly-Clark on Wednesday settled its exchange offers for all seven series of Kenvue notes, a deal that carried a cap of up to $7,000,000,000 in new Kimberly-Clark notes plus cash, according to an 8-K from Kenvue LLC. Holders who stayed in the old bonds now have far fewer protections.

What holdouts lost

Amendments to the Kenvue indenture, the contract governing the bonds, became operative at settlement. They remove substantially all restrictive covenants for each series, and certain default triggers other than failure to pay principal, premium or interest.

They also eliminate the covenant requiring Kenvue to file SEC reports, along with limits on merging into another company or transferring, leasing or conveying its assets.

The tendered notes have been retired and canceled and will not be reissued.

Tender totals by series

The largest tender was $1,478,073,000 of the 5.050% notes due 2053, leaving $21,927,000 of that series outstanding. The company said 98.54% of that series was validly tendered by expiration, the highest participation among the seven.

The 4.850% notes due 2032 drew the smallest dollar tender, $702,706,000, leaving $47,294,000. The 5.050% notes due 2028 left the biggest balance outstanding, $260,653,000, after $739,347,000 was tendered.

Remaining balances on the other series are $153,011,000 (5.000% due 2030), $97,383,000 (4.900% due 2033), $21,623,000 (5.100% due 2043) and $22,070,000 (5.200% due 2063).

Terms and the delisting

Kimberly-Clark ran the exchange under an offering memorandum dated Sept. 28, 2026, and said it had the needed consents by the Oct. 9 early participation date. Early tenderers were eligible for $970 of Kimberly-Clark notes per $1,000 of Kenvue notes, plus a $30 premium in notes and $1.00 in cash.

The swap follows Kimberly-Clark's completed acquisition of Kenvue, the maker of Tylenol, Zyrtec, Neutrogena, Listerine and other consumer health brands. Kenvue reported net sales of $15.1 billion in fiscal 2025.

The NYSE filed a Form 25-NSE on November 2 and will delist Kenvue's common stock on November 12, 2026.

Kenvue's common stock stops trading on the NYSE on November 12, 2026.

Sources

More on Kenvue

All Kenvue (KVUE) coverage →